Outcome measures for clinical trials in down syndrome

Anna J. Esbensen, Stephen R. Hooper, Deborah Fidler, Sigan L. Hartley, Jamie Edgin, Xavier Liogier D'Ardhuy, George Capone, Frances A. Conners, Carolyn B. Mervis, Leonard Abbeduto, Michael Rafii, Sharon J. Krinsky-Mchale, Tiina Urv, Elisabeth Dykens, Anna Esbenson, Sigan Hartlay, Seth Keller, Sara Weir

Research output: Contribution to journalArticle

Abstract

Increasingly individuals with intellectual and developmental disabilities, including Down syndrome, are being targeted for clinical trials. However, a challenge exists in effectively evaluating the outcomes of these new pharmacological interventions. Few empirically evaluated, psychometrically sound outcome measures appropriate for use in clinical trials with individuals with Down syndrome have been identified. To address this challenge, the National Institutes of Health (NIH) assembled leading clinicians and scientists to review existing measures and identify those that currently are appropriate for trials; those that may be appropriate after expansion of age range addition of easier items, and/or downward extension of psychometric norms; and areas where new measures need to be developed. This article focuses on measures in the areas of cognition and behavior.

Original languageEnglish (US)
Pages (from-to)247-281
Number of pages35
JournalAmerican Journal on Intellectual and Developmental Disabilities
Volume122
Issue number3
DOIs
StatePublished - May 1 2017
Externally publishedYes

Fingerprint

Down Syndrome
Outcome Assessment (Health Care)
Clinical Trials
Down syndrome
Clinical trials
Developmental Disabilities
National Institutes of Health (U.S.)
Psychometrics
Intellectual Disability
Cognition
Pharmacology
Developmental disabilities
Intellectual disability
Clinicians
Health

Keywords

  • Assessment
  • Behavior
  • Clinical trials
  • Cognition
  • Down syndrome
  • Intellectual disability

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Neuropsychology and Physiological Psychology
  • Medicine(all)
  • Developmental and Educational Psychology
  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Esbensen, A. J., Hooper, S. R., Fidler, D., Hartley, S. L., Edgin, J., D'Ardhuy, X. L., ... Weir, S. (2017). Outcome measures for clinical trials in down syndrome. American Journal on Intellectual and Developmental Disabilities, 122(3), 247-281. DOI: 10.1352/1944-7558-122.3.247

Outcome measures for clinical trials in down syndrome. / Esbensen, Anna J.; Hooper, Stephen R.; Fidler, Deborah; Hartley, Sigan L.; Edgin, Jamie; D'Ardhuy, Xavier Liogier; Capone, George; Conners, Frances A.; Mervis, Carolyn B.; Abbeduto, Leonard; Rafii, Michael; Krinsky-Mchale, Sharon J.; Urv, Tiina; Dykens, Elisabeth; Esbenson, Anna; Hartlay, Sigan; Keller, Seth; Weir, Sara.

In: American Journal on Intellectual and Developmental Disabilities, Vol. 122, No. 3, 01.05.2017, p. 247-281.

Research output: Contribution to journalArticle

Esbensen, AJ, Hooper, SR, Fidler, D, Hartley, SL, Edgin, J, D'Ardhuy, XL, Capone, G, Conners, FA, Mervis, CB, Abbeduto, L, Rafii, M, Krinsky-Mchale, SJ, Urv, T, Dykens, E, Esbenson, A, Hartlay, S, Keller, S & Weir, S 2017, 'Outcome measures for clinical trials in down syndrome' American Journal on Intellectual and Developmental Disabilities, vol 122, no. 3, pp. 247-281. DOI: 10.1352/1944-7558-122.3.247
Esbensen AJ, Hooper SR, Fidler D, Hartley SL, Edgin J, D'Ardhuy XL et al. Outcome measures for clinical trials in down syndrome. American Journal on Intellectual and Developmental Disabilities. 2017 May 1;122(3):247-281. Available from, DOI: 10.1352/1944-7558-122.3.247

Esbensen, Anna J.; Hooper, Stephen R.; Fidler, Deborah; Hartley, Sigan L.; Edgin, Jamie; D'Ardhuy, Xavier Liogier; Capone, George; Conners, Frances A.; Mervis, Carolyn B.; Abbeduto, Leonard; Rafii, Michael; Krinsky-Mchale, Sharon J.; Urv, Tiina; Dykens, Elisabeth; Esbenson, Anna; Hartlay, Sigan; Keller, Seth; Weir, Sara / Outcome measures for clinical trials in down syndrome.

In: American Journal on Intellectual and Developmental Disabilities, Vol. 122, No. 3, 01.05.2017, p. 247-281.

Research output: Contribution to journalArticle

@article{4b366deb472c4fd390efcd11b0109388,
title = "Outcome measures for clinical trials in down syndrome",
abstract = "Increasingly individuals with intellectual and developmental disabilities, including Down syndrome, are being targeted for clinical trials. However, a challenge exists in effectively evaluating the outcomes of these new pharmacological interventions. Few empirically evaluated, psychometrically sound outcome measures appropriate for use in clinical trials with individuals with Down syndrome have been identified. To address this challenge, the National Institutes of Health (NIH) assembled leading clinicians and scientists to review existing measures and identify those that currently are appropriate for trials; those that may be appropriate after expansion of age range addition of easier items, and/or downward extension of psychometric norms; and areas where new measures need to be developed. This article focuses on measures in the areas of cognition and behavior.",
keywords = "Assessment, Behavior, Clinical trials, Cognition, Down syndrome, Intellectual disability",
author = "Esbensen, {Anna J.} and Hooper, {Stephen R.} and Deborah Fidler and Hartley, {Sigan L.} and Jamie Edgin and D'Ardhuy, {Xavier Liogier} and George Capone and Conners, {Frances A.} and Mervis, {Carolyn B.} and Leonard Abbeduto and Michael Rafii and Krinsky-Mchale, {Sharon J.} and Tiina Urv and Elisabeth Dykens and Anna Esbenson and Sigan Hartlay and Seth Keller and Sara Weir",
year = "2017",
month = "5",
doi = "10.1352/1944-7558-122.3.247",
volume = "122",
pages = "247--281",
journal = "American Journal on Intellectual and Developmental Disabilities",
issn = "1944-7515",
publisher = "American Association on Intellectual and Developmental Disabilities",
number = "3",

}

TY - JOUR

T1 - Outcome measures for clinical trials in down syndrome

AU - Esbensen,Anna J.

AU - Hooper,Stephen R.

AU - Fidler,Deborah

AU - Hartley,Sigan L.

AU - Edgin,Jamie

AU - D'Ardhuy,Xavier Liogier

AU - Capone,George

AU - Conners,Frances A.

AU - Mervis,Carolyn B.

AU - Abbeduto,Leonard

AU - Rafii,Michael

AU - Krinsky-Mchale,Sharon J.

AU - Urv,Tiina

AU - Dykens,Elisabeth

AU - Esbenson,Anna

AU - Hartlay,Sigan

AU - Keller,Seth

AU - Weir,Sara

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Increasingly individuals with intellectual and developmental disabilities, including Down syndrome, are being targeted for clinical trials. However, a challenge exists in effectively evaluating the outcomes of these new pharmacological interventions. Few empirically evaluated, psychometrically sound outcome measures appropriate for use in clinical trials with individuals with Down syndrome have been identified. To address this challenge, the National Institutes of Health (NIH) assembled leading clinicians and scientists to review existing measures and identify those that currently are appropriate for trials; those that may be appropriate after expansion of age range addition of easier items, and/or downward extension of psychometric norms; and areas where new measures need to be developed. This article focuses on measures in the areas of cognition and behavior.

AB - Increasingly individuals with intellectual and developmental disabilities, including Down syndrome, are being targeted for clinical trials. However, a challenge exists in effectively evaluating the outcomes of these new pharmacological interventions. Few empirically evaluated, psychometrically sound outcome measures appropriate for use in clinical trials with individuals with Down syndrome have been identified. To address this challenge, the National Institutes of Health (NIH) assembled leading clinicians and scientists to review existing measures and identify those that currently are appropriate for trials; those that may be appropriate after expansion of age range addition of easier items, and/or downward extension of psychometric norms; and areas where new measures need to be developed. This article focuses on measures in the areas of cognition and behavior.

KW - Assessment

KW - Behavior

KW - Clinical trials

KW - Cognition

KW - Down syndrome

KW - Intellectual disability

UR - http://www.scopus.com/inward/record.url?scp=85019548074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019548074&partnerID=8YFLogxK

U2 - 10.1352/1944-7558-122.3.247

DO - 10.1352/1944-7558-122.3.247

M3 - Article

VL - 122

SP - 247

EP - 281

JO - American Journal on Intellectual and Developmental Disabilities

T2 - American Journal on Intellectual and Developmental Disabilities

JF - American Journal on Intellectual and Developmental Disabilities

SN - 1944-7515

IS - 3

ER -